KURA Q3 2024 Earnings — Kura Oncology, Inc. Revenue & Financial Results | Market Cap Arena

KURAKura Oncology, Inc.

$815M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$60M

Net Income

-$54M

EPS (Diluted)

$-0.63

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$43M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$479M

Total Liabilities

$55M

Stockholders' Equity

$424M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$216,000	+100.0%
Operating Income	-$60M	-$42M	-41.0%
Net Income	-$54M	-$39M	-40.9%